Archives of Gynecology and Obstetrics

, Volume 298, Issue 4, pp 673–674 | Cite as

Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a “useless intraoperative fever” or the next hot voice in the surgical management of the “silent killer”?

  • C. IavazzoEmail author
  • J. Spiliotis
News and Views


The aim of our opinion letter is to highlight the recent findings in the field of hyperthermic intraperitoneal chemotherapy (HIPEC) use in ovarian cancer management. Two recent studies reveal that ovarian cancer patients treated with HIPEC can extend their survival independently of the timing offered—either at the initial cytoreductive effort or at the time of disease relapse. The research field is flourishing and further data are awaited from randomised control trials. Although, HIPEC is not considered yet as the standard of care in the management of ovarian cancer patients, the initial findings of its use are promising.


Author contributions

CI concept, data analysis, writing. JS concept, data analysis, writing, supervision

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240CrossRefPubMedGoogle Scholar
  2. 2.
    Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575CrossRefPubMedGoogle Scholar
  3. 3.
    Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J (2016) Statement of the AGO Kommission Ovar, AGO study group, NOGGO, AGO Austria and AGO Switzerland regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Geburtshilfe Frauenheilkd 76(2):147–149CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Vergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1362–1363CrossRefPubMedGoogle Scholar
  5. 5.
    Ceresoli M, Frigerio L, Ansaloni L (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(14):1363PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Gynaecological Oncology DepartmentMetaxa Cancer HospitalPiraeusGreece
  2. 2.Surgical Oncology and HIPEC DepartmentAthens Medical CentreAthensGreece
  3. 3.Surgical Oncology and HIPEC DepartmentEuropean Interbalkan Medical CentreThessalonikiGreece

Personalised recommendations